The ongoing 2019 coronavirus disease (COVID-19) pandemic has disrupted care provision for patients with pain disorders, as well as those with opioid use disorder. As a result, public health experts have voiced concern that the COVID-19 pandemic may worsen the opioid crisis in the United States, and the populations affected most seriously by both crises may overlap significantly.1-3

For patients receiving treatment for addiction, access to support systems, clean needles, methadone provision, and psychiatric care may be seriously interrupted or shifted to virtual platforms.1 Furthermore, the risk of overdose may be increased during prolonged periods of heightened anxiety and isolation from peer support networks,1 as well as unemployment and socioeconomic challenges.2,3

A report released by the Well Being Trust, a non-profit foundation in the United States dedicated to advancing a vision of a nation where everyone is in mental, social and spiritual health, projected a range of 27,644 to 154,037 additional deaths of despair, including those related to drugs, alcohol, and suicide, caused by the economic downturn and social crisis stemming from the pandemic. The report advised integrating and easing access to care, as well as lowering unemployment.2

Continue Reading

The Substance Abuse and Mental Health Services Administration (SAMHSA) emphasized the importance of outpatient treatment options when possible, taking into consideration the risks of spreading COVID-19.4 SAMHSA also stressed the need for expanded telehealth services for evaluation and treatment, per Centers for Disease Control (CDC) guidance, and restrictions on buprenorphine prescriptions have been reduced.1,4

In several states, authorities have warned that overdoses may be rising during the COVID-19 pandemic, and a lack of data may mean that overdoses involving opioids are nearly 30% higher than reported.5-6 Overdoses in recent years have been driven largely by synthetic opioids like fentanyl, and the opioid crisis has affected more and more communities across the nation.6

To learn more about these overlapping crises, we interviewed pain specialist Paul J. Christo, MD, MBA, the Director of the Multidisciplinary Pain Fellowship Program at Johns Hopkins Hospital in Baltimore, Maryland. Dr Christo is also the host of the Aches and Gains Radio Talk Show on Sirius XM.

What effect has the COVID-19 pandemic had on the ongoing opioid epidemic?

Paul J. Christo, MD, MBA: The most recent data indicate that there has been an increase in opioid related deaths. The deaths are mainly related to synthetic opioids and not prescription opioids. Specifically, the deaths are due to illicitly manufactured fentanyl, which is a potent opioid and much more powerful than morphine, for instance.

We’ve seen counterfeit drugs like oxycodone laced with fentanyl available illegally on the street, and even illegal drugs like cocaine and methamphetamine have been laced with fentanyl. The combination of these substances is lethal.

Have there been any problems with data availability or reporting on opioid addiction and overdoses since the start of the pandemic?

Dr Christo: Yes. Most health care resources have been diverted to reporting on COVID-19 exposures, protection, and treatment.

What have health systems and government agencies done to counter the apparent rise in opioid overdoses during the pandemic? Is there anything they are not currently doing that you support implementing?

Dr Christo: The CDC is providing funding to collect data on drug overdoses, and then target public health response efforts to areas of need. I think that government agencies and public health systems need to better disseminate naloxone (narcan), the opioid reversal medicine, to rural communities that are seeing more and more overdose deaths.

Physicians and health care providers can prescribe narcan, and many states allow pharmacists to dispense it. Law enforcement agencies can also provide narcan. We need better awareness of its life saving ability so that those at risk make sure they get it. Emergency funding from the government to support behavioral health services needs to occur so that mental health professionals can remain available to treat patients with addiction.

The COVID-19 pandemic has taken a serious socioeconomic toll on communities already experiencing hardship, which has been cited as a major factor in the opioid crisis. What needs to happen to help address these challenges?

Dr Christo: Making sure that those in these communities take advantage of expanding teletherapy services for mental health. Telemedicine services have expanded during COVID-19 and provide vital support services, counseling, therapy, and group support. Certainly, as jobs return and the economy rebounds, we will see fewer people turning to mind and mood altering substances as coping strategies.

For patients with chronic pain and other conditions, opioid drugs are critical. Have patients experienced barriers to accessing regular medications over this period?

Dr Christo: Yes. At the outset of the pandemic, physician offices were closed and patients had difficulty accessing their needed medications for pain such as opioids, or procedural treatments like nerve blocks, or injections. Fortunately, the United States Drug Enforcement Administration (DEA) Division of Diversion Control fairly quickly allowed opioids and other controlled substances to be prescribed via telemedicine without an in-person medical evaluation as long as certain conditions were met.

This article originally appeared on MPR